A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00219193
- Lead Sponsor
- Novartis
- Brief Summary
To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 641
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after 8 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in standing blood pressure after 4 weeks and 8 weeks Change from baseline in systolic and diastolic blood pressure after 4 weeks and 8 weeks Achieve blood pressure control target of < 140/90 mmHg after 8 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does the triple combo of Aliskiren/Valsartan/HCTZ modulate RAAS pathways compared to dual therapies in hypertension?
What is the comparative efficacy of Aliskiren/Valsartan/HCTZ versus standard dual combos in HCTZ-resistant hypertension?
Which biomarkers predict response to Aliskiren/Valsartan/HCTZ in RAAS pathway dysregulated hypertension?
What are the management strategies for hyperkalemia in Aliskiren/Valsartan/HCTZ combination therapy?
How does the Novartis triple combo compare to other RAAS inhibitor combinations in treatment-resistant hypertension?
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States